Why Zero for Two matters: no antibody-drug conjugate has faced a biosimilar challengeyet.
In the patent-and-paragraphs world, zero can be a signalor a trap. The industry has long been told that as biologics mature, biosimilars are inevitable. But a g…
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar Read Post »
CRISPR was supposed to be protected by platform patents. Fourteen years later, the litigation story says: not really.
For years, the gene-editing industry has operated on a kind of legal common sense: broad, platform patents would establish stable grou…
Stop Tracking Drug Patents. Start Tracking Who Controls Them.
Most people in pharma analytics think the clock starts with a filing.
A patent application lands, a priority date is logged, an expiry estimate gets modeled, a downstream event is scheduled …
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
No AI Has Ever Been Named an Inventor on a Drug PatentHeres the Rule That Makes That Almost Impossible
For years, the AI question in pharma has sounded like a thought experiment: If an algorithm designs a molecule, shouldnt the system be listed as an i…
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. Read Post »
Google Patents wasnt built for pharma. Heres what it misses every time you search a drug name.
Pharma teams dont Google patentsthey interrogate them.
Yet the moment you type a molecule, a brand name, or an ingredient into Google Patents, youre likely g…
Google Patents Wasnt Built for PharmaHeres What It Misses Every Time You Search a Drug Name
Most people search Google the way they search for truth: type a name, hit enter, and assume the system will surface what matters.
But if youre in pharmaregula…
If your team is still manually cross-referencing patents to find whats in scope, you may be bleeding hoursand momentumwithout realizing it.
Thats the quiet failure mode many IP, legal ops, and competitive intelligence teams fall into: treating patent d…
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing Read Post »
Most pharma leaders have a spreadsheet problem.
It starts innocently: a tidy table of patent and exclusivity expiration dates, neatly color-coded and owned by someone on the commercial ops side or external counsel. Quarterly updates. Annual audits. May…
ð¨ The three-week bottleneck isnt a workload problemits a process problem.
In an era when drug approvals, reimbursement decisions, and competitive launches move at the speed of data, waiting three weeks for an analyst report that should have taken …
Drug development doesnt miss deadlines by accidentit misses them because the system is built to reward precision and punish assumptions.
Every year, companies look up and realize they somehow missed a key NCE 1 datejust as the quarterly review turns fr…
Get new actionable insights and updates from BiotechBlog
